These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 26354016)

  • 1. [Preclinical and clinical properties of vaniprevir (VANIHEP® Capsules 150 mg), a novel therapeutic agent for hepatitis C].
    Kinoshita K; Iwasa T; Takase A; Nakamura K
    Nihon Yakurigaku Zasshi; 2015 Sep; 146(3):159-70. PubMed ID: 26354016
    [No Abstract]   [Full Text] [Related]  

  • 2. [Pharmacological properties of simeprevir (SOVRIAD® capsules 100 mg), a new drug for the treatment of hepatitis C, and results of its clinical studies].
    Nagino K; Tsutsumi K; Ishido M; Harada Y
    Nihon Yakurigaku Zasshi; 2015 Feb; 145(2):92-9. PubMed ID: 25747021
    [No Abstract]   [Full Text] [Related]  

  • 3. HCV evolutionary genetics of SVR versus virologic failure assessed from the vaniprevir phase III registration trials.
    Ludmerer SW; Hirano T; Black S; Howe AY; Chang W; Takase A; Nakamura K; Tanaka Y; Kumada H; Hayashi N; Nickle D
    Antiviral Res; 2016 Jun; 130():118-29. PubMed ID: 26947564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emergence of resistance-associated variants after failed triple therapy with vaniprevir in treatment-experienced non-cirrhotic patients with hepatitis C-genotype 1 infection: a population and clonal analysis.
    Barnard RJ; McHale CM; Newhard W; Cheney CA; Graham DJ; Himmelberger AL; Strizki J; Hwang PM; Rivera AA; Reeves JD; Nickle D; Dinubile MJ; Hazuda DJ; Mobashery N
    Virology; 2013 Sep; 443(2):278-84. PubMed ID: 23763767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: safety, antiviral activity, resistance, and pharmacokinetics.
    Lawitz E; Sulkowski M; Jacobson I; Kraft WK; Maliakkal B; Al-Ibrahim M; Gordon SC; Kwo P; Rockstroh JK; Panorchan P; Miller M; Caro L; Barnard R; Hwang PM; Gress J; Quirk E; Mobashery N
    Antiviral Res; 2013 Sep; 99(3):214-20. PubMed ID: 23747481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A case of successful treatment with telaprevir-based triple therapy for hepatitis C infection after treatment failure with vaniprevir-based triple therapy.
    Takayama K; Furusyo N; Ogawa E; Shimizu M; Hiramine S; Mitsumoto F; Ura K; Toyoda K; Murata M; Hayashi J
    J Infect Chemother; 2014 Sep; 20(9):577-81. PubMed ID: 25000830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel hepatitis C drugs in current trials.
    Kronenberger B; Welsch C; Forestier N; Zeuzem S
    Clin Liver Dis; 2008 Aug; 12(3):529-55, viii. PubMed ID: 18625427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaniprevir plus peginterferon alfa-2b and ribavirin in treatment-experienced Japanese patients with hepatitis C virus genotype 1 (GT1b) infection: Phase 3 studies.
    Kumada H; Mochida S; Suzuki F; Chayama K; Karino Y; Nakamura K; Fujimoto G; Howe AY; Ludmerer SW; Mobashery N
    J Gastroenterol Hepatol; 2016 Oct; 31(10):1674-1683. PubMed ID: 26936417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Expert advices for evaluating clinical trials of direct-acting antiviral agents for hepatitis C].
    Research Group for New Drug's Clinical Evalutaion of Critical Diseases and Platform Construction of Integrated Technology
    Zhonghua Gan Zang Bing Za Zhi; 2016 Mar; 24(3):161-4. PubMed ID: 27095756
    [No Abstract]   [Full Text] [Related]  

  • 10. [Treatment choice of the antiviral agent for the hepatitis C].
    Karino Y
    Nihon Rinsho; 2015 Dec; 73 Suppl 9():269-73. PubMed ID: 26845943
    [No Abstract]   [Full Text] [Related]  

  • 11. Does fluvastatin favour HCV replication in vivo? A pilot study on HIV-HCV co-infected patients.
    Bader T
    J Viral Hepat; 2010 Mar; 17(3):227. PubMed ID: 19758277
    [No Abstract]   [Full Text] [Related]  

  • 12. In vivo effects of fluvastatin on HCV replication in HIV-1 coinfected subjects.
    Milazzo L; Antinori S
    J Viral Hepat; 2010 Mar; 17(3):228. PubMed ID: 19758276
    [No Abstract]   [Full Text] [Related]  

  • 13. Challenges and successes in developing new therapies for hepatitis C.
    De Francesco R; Migliaccio G
    Nature; 2005 Aug; 436(7053):953-60. PubMed ID: 16107835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent advances in the discovery of small molecule therapies for HCV.
    Myles DC
    Curr Opin Drug Discov Devel; 2001 Jul; 4(4):411-6. PubMed ID: 11727306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Practical consequences of hepatitis C virus quasispecies for target-specific antivirals.
    Fanning LJ
    J Infect Dis; 2008 Sep; 198(6):797-9. PubMed ID: 18637751
    [No Abstract]   [Full Text] [Related]  

  • 16. Tailoring antiviral therapy in hepatitis C.
    Davis GL
    Hepatology; 2006 May; 43(5):909-11. PubMed ID: 16628667
    [No Abstract]   [Full Text] [Related]  

  • 17. Hepatitis C virus virology and new treatment targets.
    Meier V; Ramadori G
    Expert Rev Anti Infect Ther; 2009 Apr; 7(3):329-50. PubMed ID: 19344246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment duration for genotypes 2 and 3: still confusing after all these years.
    Jensen DM
    J Clin Gastroenterol; 2010 Sep; 44(8):527-8. PubMed ID: 20628314
    [No Abstract]   [Full Text] [Related]  

  • 19. Hepatitis C virus infection in Taiwan: Past, present, and future.
    Kao JH
    J Formos Med Assoc; 2016 Feb; 115(2):65-6. PubMed ID: 26228687
    [No Abstract]   [Full Text] [Related]  

  • 20. [BMS-790 052 - an oral antiviral hepatitis C antiviral in the pipeline].
    Schmitz J
    Pharm Unserer Zeit; 2011 Jan; 40(1):8-9. PubMed ID: 21194074
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.